Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigation of Pharmacokinetics, Safety, and Tolerability of a Single Oral 25 mg BAY 1142524 IR Tablet Dose in Male and Female Subjects With Renal Impairment and in Age-, Gender-, and Weight-matched Healthy Subjects in a Single Center, Non-controlled, Open-label, Observational Design

NCT03402438 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT03402438
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03402438 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigation of Pharmacokinetics, Safety, and Tolerability of a Single Oral 25 mg BAY 1142524 IR Tablet Dose in Male and Female Subjects With Renal Impairment and in Age-, Gender-, and Weight-matched Healthy Subjects in a Single Center, Non-controlled, Open-label, Observational Design
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
February 12, 2018
Completion date
March 19, 2019
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical trial, phase i